Manzanita Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Manzanita Pharmaceuticals is a private, pre-revenue biotech leveraging a proprietary platform to create neurotrophin-dye and neurotrophin-drug conjugates. Its primary focus is on developing NerveLight, a near-infrared (NIR) imaging agent for intraoperative nerve visualization, initially targeting prostatectomy to reduce complications like impotence and incontinence. Founded in 1982 (re-established in 2007), the company has been funded primarily through non-dilutive grants and angel investment, and is led by a small team with strong academic and entrepreneurial backgrounds. The technology platform promises applications beyond imaging, including novel drug delivery for pain and other neurological conditions.

OncologyNeurologyPain

Technology Platform

Platform for conjugating generic small-molecule dyes or drugs to recombinant human neurotrophins (rhNGF, rhBDNF) for targeted delivery to neurons.

Opportunities

The company addresses a significant unmet need in surgical oncology with no FDA-approved nerve imaging agents currently available.

Its platform's compatibility with existing surgical imaging hardware presents a lower adoption barrier and a faster potential path to market.

The technology also opens a vast long-term opportunity in targeted drug delivery for neurological conditions and pain.

Risk Factors

The company is at a pre-clinical stage with unproven clinical efficacy and safety for its lead candidate.

It faces significant regulatory uncertainty as a first-in-class agent and is likely undercapitalized, having raised only ~$4M primarily from grants and angels, which may be insufficient to fund clinical trials.

Competitive Landscape

The field of fluorescence-guided surgery is growing, with agents targeting tumors, blood flow, and other tissues, but NerveLight appears unique in its specific focus on peripheral nerve imaging. Potential competitors include academic groups and companies developing alternative nerve visualization techniques (e.g., confocal microscopy, other targeted dyes), but no direct, neurotrophin-conjugated NIR agent is known to be in clinical development.

More companies in Small Molecule Drugs →More companies in United States →